Search

Displaying results 2801 - 2810 of 7897 in total
  1. Drug

    Pyrazinamide

    go.drugbank.com/drugs/DB00339
    ApprovedInvestigational

    A pyrazine that is used therapeutically as an antitubercular agent.

    Mixtures: PRO TB 4, PRO TB 3 KIDProducts: TB ZET
  2. Drug

    DG051

    go.drugbank.com/drugs/DB05177
    Experimental

    DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. … DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation.

  3. Drug

    Cholic Acid

    go.drugbank.com/drugs/DB02659
    ApprovedInvestigational

    [PubChem] Cholic acid, formulated as Cholbam capsules, is approved by the United States Food and Drug Administration as a treatment for children and adults with bile acid synthesis disorders due to single … enzyme defects, and for peroxisomal disorders (such as Zellweger syndrome).

  4. Drug

    Doxapram

    go.drugbank.com/drugs/DB00561
    ApprovedInvestigationalVet approved

    A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)

  5. Drug

    Brigatinib

    go.drugbank.com/drugs/DB12267
    ApprovedInvestigational

    Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). … [A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026]

    Categories: Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  6. Drug

    TTP889

    go.drugbank.com/drugs/DB05131
    Investigational

    TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. … TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic pathway of the blood coagulation system.

  7. Drug

    Cefiderocol

    go.drugbank.com/drugs/DB14879
    ApprovedInvestigational

    Cefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics. … [A189150] A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Crotalus adamanteus antivenin

    go.drugbank.com/drugs/DB13893
    Approved

    Crotalus adamanteus antivenin is derived and purified immunoglobulin fragments obtained from other domestic animals such as sheep previously immunized with Crotalus adamanteus (Eastern Diamondback rattlesnake

    Synonyms: Crotalus adamanteus immune fab antivenin (ovine)
  9. Drug

    Vorinostat

    go.drugbank.com/drugs/DB02546
    ApprovedInvestigational

    It is the first in a new class of agents known as histone deacetylase inhibitors. … Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease

  10. Drug

    Roxarsone

    go.drugbank.com/drugs/DB11458
    ExperimentalVet approved

    The addition of this compound to poultry feed improves weight gain and feed efficiency as well as prevent the growth of coccidian parasites. … Roxarsone is an organoarsenic molecule added to poultry feed.